- Home
- CNOB vs VCEL Comparison
CNOB vs VCEL Comparison
Compare CNOB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | VCEL |
|---|---|---|
| Founded | 1982 | 1989 |
| Country | United States | United States |
| Employees | 756 | 398 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CNOB | VCEL |
|---|---|---|
| Price | $29.79 | $35.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $31.25 | ★ $57.75 |
| AVG Volume (30 Days) | 301.8K | ★ 585.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $42.85 | $19.40 |
| Revenue Next Year | $7.27 | $18.24 |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $21.82 | $28.95 |
| 52 Week High | $30.65 | $45.97 |
Technical Indicators
Market Signals| Indicator | CNOB | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 53.94 |
| Support Level | $24.76 | $34.30 |
| Resistance Level | $30.65 | $38.31 |
| Average True Range (ATR) | 0.76 | 1.95 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 69.53 | 36.76 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.